We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Neuromodulation System Helps Treat Fecal Incontinence

By HospiMedica International staff writers
Posted on 14 Jan 2020
A new neuromodulation system treats patients with fecal incontinence (FI) by targeting the tibial nerve, located near the ankle.

The Bioness (Valencia, CA, USA) StimRouter neuromodulation system is a minimally invasive device consisting of a thin, implanted lead fitted with a conductive electrode, an external pulse transmitter (EPT), and a hand-held wireless patient programmer and controller. More...
Electrical signals are transmitted transdermally from the EPT to a disposable user patch, down the electrical lead to the implanted electrode, and from there to the area of tibial nerve. A typical session lasts 15 to 20 minute, depending on the stimulation program selected.

StimRouter is programmed at the direction of the physician, but it is controlled by the patient to address the specific, changing pain management needs. Small and unobtrusive, the patient programmer creates a wireless connection to the EPT, allowing patients to easily turn the stimulation on or off, increase and decrease stimulation intensity, and select from up to eight stored, custom stimulation programs. An LCD display allows the patients to monitor and manage their stimulation programs and level of intensity. The system can also be used treat chronic pain and overactive bladder (OAB).

“The StimRouter is changing the lives of patients who are looking for new ways to treat not just their pain but also life-impacting conditions, such as fecal incontinence and overactive bladder,” said Todd Cushman, President and CEO of Bioness. “The clinical understanding of stimulating peripheral nerves is allowing for innovative uses of the StimRouter device in Europe, as well as potentially expanding its use in the United States beyond our current chronic pain indication in the future.”

FI and urinary incontinence (UI) constitute a major health problem affecting the lives of an estimated 400 million persons worldwide. Incontinence is also more prevalent in men and women affected by various neurological illnesses, such as multiple sclerosis, spina bifida, Parkinson’s disease, and stroke. Global demographic trends suggest that the incidence of both UI and FI will rise in the coming years, with a significant health and social burden as well as an increased economic cost for both patients and health service payers.

Related Links:
Bioness


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.